Overview Dividends

(BIIB) Biogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062X1037

Multiple Sclerosis Drugs, Spinal Muscular Atrophy Therapy, Biosimilars, Alzheimers Pipeline, Oncology Antibodies

Biotechnology
Market Cap in USD: 25,541m

IPO / Inception: 1991-09-16
Return 12m vs S&P 500: -0.89%

EPS (Earnings per Share)

EPS CAGR: 9.78%
EPS Trend: 1.0%

Last SUE: 1.64
Qual. Beats: 2

Revenue

Rev. CAGR: -2.83%
Rev. Trend: -41.2%

Last SUE: 0.86
Qual. Beats: 3

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	32.9%
Value at Risk 5%th	52.5%
Relative Tail Risk	-2.85%

Reward TTM
Sharpe Ratio	0.40
Alpha	3.82
CAGR/Max DD	-0.24

Character TTM
Hurst Exponent	0.501
Beta	0.565
Beta Downside	0.482

Drawdowns 3y
Max DD	64.35%
Mean DD	33.73%
Median DD	32.46%

Description: BIIB Biogen December 19, 2025

Biogen (NASDAQ: BIIB) is a global biotech firm that discovers, develops, manufactures, and commercializes therapies for neurological and neuro-degenerative diseases, with a footprint across the United States, Europe, Asia and other regions.

Its core marketed portfolio includes multiple-sclerosis drugs (Tecfidera, Vumerity, Avonex, Plegridy, Tysabri), the SMA treatment Spinraza, the Friedreich’s ataxia candidate Skyclarys, ALS therapy Qalsody, and a suite of biosimilars (Benepali, Imraldi, Flixabi, Byooviz, Tofidence). In oncology, Biogen sells Rituxan, Rituxan Hycela, Gazyva, Ocrevus, and emerging anti-CD20 agents such as glofitamab.

Beyond current products, the company is advancing pipelines in MS, Alzheimer’s disease (notably lecanemab, which generated $1.1 billion in 2023 U.S. sales), Parkinson’s disease, and other neuro-psychiatric indications, while expanding its biosimilar franchise.

Key financial metrics (FY 2023): revenue $10.6 billion, R&D spend ≈ 22 % of revenue, and a diluted EPS of $3.21. In Q2 2024, Tecfidera net sales fell 12 % YoY, reflecting competitive pressure and the rollout of generic alternatives.

Sector drivers that materially affect Biogen’s outlook include the aging global population (projected to increase the prevalence of neuro-degenerative disorders by ~30 % over the next decade) and U.S. Medicare reimbursement reforms that tighten pricing for high-cost biologics.

For a data-rich, analyst-level deep-dive on Biogen’s valuation sensitivities, the ValueRay platform offers a transparent, model-backed view worth exploring.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (1.61b TTM) > 0 and > 6% of Revenue (6% = 599.2m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 1.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.55% (prev 14.63%; Δ 41.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 2.45b > Net Income 1.61b (YES >=105%, WARN >=100%)

Net Debt (2.73b) to EBITDA (3.49b) ratio: 0.78 <= 3.0 (WARN <= 3.5)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (147.1m) change vs 12m ago 0.82% (target <= -2.0% for YES)

Gross Margin 70.12% (prev 71.78%; Δ -1.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.72% (prev 33.93%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 10.50 (EBITDA TTM 3.49b / Interest Expense TTM 260.0m) >= 6 (WARN >= 3)

Altman Z'' 6.15

(A) 0.19 = (Total Current Assets 8.94b - Total Current Liabilities 3.29b) / Total Assets 29.21b

(B) 0.71 = Retained Earnings (Balance) 20.60b / Total Assets 29.21b

(D) 1.85 = Book Value of Equity 20.39b / Total Liabilities 11.00b

Total Rating: 6.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.75

1. Piotroski 6.0pt

2. FCF Yield 8.08%

3. FCF Margin 22.81%

4. Debt/Equity 0.36

5. Debt/Ebitda 0.78

6. ROIC - WACC (= 3.04)%

7. RoE 9.25%

8. Rev. Trend -41.22%

9. EPS Trend 0.98%

What is the price of BIIB shares?

As of December 19, 2025, the stock is trading at USD 169.91 with a total of 2,760,852 shares traded.
Over the past week, the price has changed by -1.50%, over one month by +0.64%, over three months by +18.15% and over the past year by +15.75%.

Is BIIB a buy, sell or hold?

Biogen has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BIIB.

Strong Buy: 13
Buy: 4
Hold: 20
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BIIB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	180.2	6%
Analysts Target Price	180.2	6%
ValueRay Target Price	170.8	0.5%

BIIB Fundamental Data Overview December 13, 2025

Market Cap USD = 25.54b (25.54b USD * 1.0 USD.USD)
P/E Trailing = 15.7272
P/E Forward = 11.0375
P/S = 2.5374
P/B = 1.3899
P/EG = 5.0169
Beta = 0.128
Revenue TTM = 9.99b USD
EBIT TTM = 2.73b USD
EBITDA TTM = 3.49b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 1.75b USD (from shortTermDebt, last fiscal year)
Debt = 6.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.73b USD (from netDebt column, last quarter)
Enterprise Value = 28.17b USD (25.54b + Debt 6.59b - CCE 3.96b)
Interest Coverage Ratio = 10.50 (Ebit TTM 2.73b / Interest Expense TTM 260.0m)
FCF Yield = 8.08% (FCF TTM 2.28b / Enterprise Value 28.17b)
FCF Margin = 22.81% (FCF TTM 2.28b / Revenue TTM 9.99b)
Net Margin = 16.11% (Net Income TTM 1.61b / Revenue TTM 9.99b)
Gross Margin = 70.12% ((Revenue TTM 9.99b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 64.23%)
Tobins Q-Ratio = 0.96 (Enterprise Value 28.17b / Total Assets 29.21b)
Interest Expense / Debt = 1.02% (Interest Expense 67.4m / Debt 6.59b)
Taxrate = 16.29% (90.8m / 557.3m)
NOPAT = 2.29b (EBIT 2.73b * (1 - 16.29%))
Current Ratio = 2.72 (Total Current Assets 8.94b / Total Current Liabilities 3.29b)
Debt / Equity = 0.36 (Debt 6.59b / totalStockholderEquity, last quarter 18.21b)
Debt / EBITDA = 0.78 (Net Debt 2.73b / EBITDA 3.49b)
Debt / FCF = 1.20 (Net Debt 2.73b / FCF TTM 2.28b)
Total Stockholder Equity = 17.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.51% (Net Income 1.61b / Total Assets 29.21b)
RoE = 9.25% (Net Income TTM 1.61b / Total Stockholder Equity 17.38b)
RoCE = 11.53% (EBIT 2.73b / Capital Employed (Equity 17.38b + L.T.Debt 6.29b))
RoIC = 9.65% (NOPAT 2.29b / Invested Capital 23.67b)
WACC = 6.61% (E(25.54b)/V(32.13b) * Re(8.10%) + D(6.59b)/V(32.13b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
[DCF Debug] Terminal Value 80.02% ; FCFE base≈2.07b ; Y1≈2.39b ; Y5≈3.35b
Fair Price DCF = 390.5 (DCF Value 57.28b / Shares Outstanding 146.7m; 5y FCF grow 17.62% → 3.0% )
EPS Correlation: 0.98 | EPS CAGR: 9.78% | SUE: 1.64 | # QB: 2
Revenue Correlation: -41.22 | Revenue CAGR: -2.83% | SUE: 0.86 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.54 | Chg30d=+0.042 | Revisions Net=-4 | Analysts=13
EPS next Year (2026-12-31): EPS=15.21 | Chg30d=+0.004 | Revisions Net=-13 | Growth EPS=+0.9% | Growth Revenue=-5.2%

Additional Sources for BIIB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle